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A B S T R AC T
Background: Of all hospitalised community-acquired 
pneumonias (CAPs) only a few are known to be caused 
by Chlamydia psittaci. Most likely the reported incidence, 
ranging from of 0% to 2.1%, is an underestimation of the 
real incidence, since detection of psittacosis is frequently 
not incorporated in the routine microbiological diagnostics 
in CAP or serological methods are used.
Methods: C. psittaci real-time polymerase chain reaction 
(PCR) was routinely performed on the sputum of 147 
patients hospitalised with CAP, who participated in a 
clinical trial conducted in two Dutch hospitals. In 119/147 
patients the paired complement fixation test (CFT) was 
also performed for the presence of Chlamydia antibodies. 
Positive CFTs were investigated by micro-immuno-
fluorescence for psittacosis specificity. Case criteria for 
psittacosis were a positive PCR or a fourfold rise of 
antibody titre in CFT confirmed by micro-immuno-
fluorescence. Furthermore, we searched for parameters 
that could discriminate psittacosis from CAPs with other 
aetiology.
Results: 7/147 (4.8%) patients were diagnosed with 
psittacosis: six with PCR and one patient with a negative 
PCR, but with CFT confirmed by micro-immunofluo-
rescence. Psittacosis patients had had a higher temperature 
(median 39.6 vs. 38.2 °C;) but lower white blood cell count 
(median 7.4 vs. 13.7 x109/l) on admission compared with 
other CAP patients. 
Conclusion: In this study, C. psittaci as CAP-causing 
pathogen was much higher than previously reported. 
To detect psittacosis, PCR was performed on all CAP 
patients for whom a sputum sample was available. For 
clinical use, PCR is a fast method and sputum availability 
allows genotyping; additional serology can optimise 
epidemiological investigations.
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I N T RODUC T I ON
Chlamydia psittaci is an intra-cellular Gram-negative 
bacterium which may cause zoonotic pneumonia in 
humans.1 Usually, transmission occurs through inhalation 
of aerosols from contaminated bird substances such as 
droppings, plumage, or tissue.2 Few studies have evaluated 
the incidence of C. psittaci in hospitalised community-
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acquired pneumonia (CAP); reported incidence rates 
range from 0% in Korea in the years 1999-2000,3 to 
0.002% in Australia in 2004-2006,4 0.004% in Canada 
in 1996-1997,5 and 0.36% in Spain in 1996-1997.6 
These rates are probably an underestimation of the true 
incidence since even brief exposure can lead to systemic 
infection7 and testing for C. psittaci is often only included 
in the diagnostic algorithm if the clinician is aware of 
contact with birds in the patient’s history. Although the 
disease is notifiable to the public health authorities in 
the Netherlands, detection of psittacosis is frequently not 
incorporated in routine microbiological diagnostic panels 
for pneumonia. Since standard β-lactam based antibiotic 
therapy is not adequate for the treatment of C. psittaci, this 
might lead to progression of infection. 
Psittacosis can be diagnosed by culture, but C. psittaci 
is difficult to grow. Furthermore, biosafety level three 
facilities and cell cultures are required which are not 
available in most medical microbiology laboratories. 
Currently, polymerase chain reaction (PCR) of sputum 
or bronchial secretions and serology are the cornerstones 
of microbiological diagnosis. All aforementioned studies 
on psittacosis incidence used only serological diagnostic 
methods such as complement fixation test (CFT) and 
micro-immunofluorescence. Due to the retrospective 
aspect and cross-reactivity with other Chlamydia species, 
detection by serology is not optimal. If sputum is available, 
PCR is a method with fast results and lacking genus 
broad cross-reactivity.8 The availability of sputum enables 
genotyping of the strain. A recent study from Germany 
reported a C. psittaci incidence of 2.1% in CAP, based on 
C. psittaci PCR on pharyngeal swabs in all CAP patients 
who presented to the emergency department.9 
We analysed a cohort of 304 patients hospitalised with 
CAP in which PCR and CFT for psittacosis diagnosis were 
incorporated in the diagnostic algorithm. We also analysed 
whether specific clinical parameters were associated with 
CAP caused by C. psittaci. Furthermore, we evaluated the 
contribution of serology to the diagnosis of psittacosis by 
PCR. 
MAT E R I A L S  A N D  M E T HODS
Study design and patients
Our analyses were performed in all patients in whom a 
sputum or bronchoalveolar lavage sample was available 
in a cohort of 304 hospitalised patients with CAP who 
participated in a randomised clinical trial conducted in 
the Netherlands from November 2007 until September 
2010 (NCT00471640). The original trial investigated 
the adjunctive treatment of dexamethasone 5 mg given 
intravenously. Detailed inclusion and exclusion criteria 
are described elsewhere.10 In summary, patients with 
CAP admitted to the St. Antonius Hospital (Nieuwegein, 
the Netherlands) or the Gelderse Vallei Hospital (Ede, 
the Netherlands) were included. Pneumonia was defined 
as a new pulmonary infiltrate on chest radiograph, in 
combination with at least two of the following criteria: 
cough, sputum production, temperature > 38.0 °C or < 35.0 
°C, auscultatory findings consistent with pneumonia, 
C-reactive protein concentration > 15 mg/l, and white blood 
cell count > 10 x 109 cells/l or < 4 x 109 cells/l or > 10% 
of rods in leukocyte differentiation. Patients who were 
immunocompromised, who were admitted to the intensive 
care unit immediately, or who received immunosup-
pressive therapy were excluded. The study was approved by 
the local Medical Ethics Committees of both hospitals and 
all patients gave written informed consent. 
Psittacosis diagnosis
Sputum or bronchoalveolar lavage was analysed with C. 
psittaci specific real-time PCR.11 Furthermore, acute-phase 
serum and convalescent serum samples were analysed 
for the presence of antibodies against Chlamydia species, 
with CFT using a Chlamydia-specific lipopolysaccharide 
(Virion-Serion, Ruschlikon, Switzerland). The interval 
between the first (day of admission) and second serum 
sample was at least ten days with a maximum of 120 days. 
A fourfold or greater rise of the antibody titre in the 
convalescent versus the acute-phase serum was considered 
indicative for a recent Chlamydia infection (sequence 1: 
< 4, 4, 8, 16, etc. or 1: < 10, 10, 20, 40, etc.). Sera of patients 
with a positive psittacosis PCR or CFT result were tested 
with micro-immunofluorescence (Focus Diagnostics, 
United States of America), using the same criteria for a 
rise in antibody titre that were used for CFT (sequence 1: 
< 16, 16, 32, 64, etc.). The case criteria for a diagnosis of 
psittacosis was a positive PCR or a fourfold rise of antibody 
titre in CFT confirmed by micro-immunofluorescence. 
Stored sputum samples were genotyped by partial ompA 
gene sequencing.12 
Diagnosis of other respiratory pathogens
Two sets of separate blood samples and sputum samples 
were cultured. Urine antigen tests were performed for 
the detection of Streptococcus pneumoniae and Legionella 
pneumophila serogroup 1. Real-time PCRs on sputum were 
also performed to detect Legionella species, Mycoplasma 
pneumoniae and Coxiella burnetii. Moreover, St. Antonius 
Hospital samples were also tested for C. pneumoniae until 
November 2008. Acute versus convalescent serological 
testing was performed for antibodies to M. pneumoniae, 
C. burnetii and respiratory viruses (adenovirus, influenza 
virus A and B, parainfluenza virus 1, 2 and 3, and the 
respiratory syncytial virus). Pharyngeal swabs were taken 
for PCR to detect (para)-influenza virus, adenovirus and 
respiratory syncytial virus.
Spoorenberg et al. Chlamydia psittaci as cause of pneumonia.
77
F E B R U A R Y  2 0 1 6 ,  V O L .  7 4 ,  N O  2
The Netherlands Journal of Medicine
Spoorenberg et al. Chlamydia psittaci as cause of pneumonia.
Clinical parameters and outcome
Clinical and laboratory parameters (table 1) were 
documented. For patients in whom information on bird 
contact was not available in the admission documents, the 
Dutch notification database of the Centre for Infectious 
Disease Control of reported psittacosis patients was 
checked for information on this subject.
Statistical analyses
Overall, descriptives were stated as number (%) or 
median (interquartile range (IQR)). Patient characteristics 
between psittacosis patients and other aetiology were 
compared using Chi-square test, Fisher’s exact test, or 
Mann-Whitney U test, where appropriate. For this analysis, 
a p-value < 0.002 was considered significant, using 
Table 1. Baseline characteristics of 147 patients hospitalised with community-acquired pneumonia categorised in 
psittacosis versus non-psittacosis pneumonia
Characteristics Psittacosis 
(n = 7)
Other aetiology 
(n = 140)
Odds ratio (95% CI)
Age in years (IQR) 54 (46-58) 64 (51-76) 0.96 (0.92-1.00)
Male sex (%) 5 (71.4) 81 (57.9) 1.82 (0.34-9.71)
Smoking (%)∞ 2 (28.6) 47 (33.6) 1.21 (0.20-7.47)
Nursing home resident (%) 0 3 (2.1) NA
Season of admission (%)
Summer
Winter
Spring
Autumn
1 (14.3)
1 (14.3)
4 (57.1)
1 (14.3)
22 (15.7)
46 (32.9)
50 (35.7)
22 (15.7)
0.48 (0.03-8.01)
1.76 (0.19-16.66)
1.00 (0.06-17.02)
Comorbidities (%)
COPD
Congestive heart failure
Renal disease
Diabetes mellitus
Liver disease
0
0
0
0
0
21 (15.0)
21 (15.0)
11 (7.9)
21 (15.0)
1 (0.7)
NA
NA
NA
NA
NA
Days of illness (IQR)* 5.0 (3.0-5.0) 5.0 (3.0-7.0) 0.88 (0.36-2.16)
Physical examination (IQR)
Systolic BP in mmHg 
Diastolic BP in mmHg 
Pulse rate in beats/min
Temperature in °C
133 (125-149)
9 (65-82)
112 (90-120)
39.6 (38.8-40.0)
130 (116-145)
75 (64-83)
98 (84-111)
38.2 (37.4-38.9)
1.00 (0.97-1.04)
1.01 (0.95-1.08)
1.03 (0.99-1.08)
4.25 (1.46-12.35)
Laboratory parameters
CRP in mg/l (IQR)*
WBC count x109/l (IQR)
Creatinine in µmol/l (IQR)*
BUN in mg/dl (IQR)*
Sodium in mmol/l (IQR)
ASAT in U/l (IQR)*
Glucose in mmol/l (IQR)*
IL-6 in pg/ml (IQR)*
335 (221-359)
7.4 (6.9-10.4)
95 (106-70)
5.3 (4.0-6.9)
127 (122-132)
46 (24-154)
8.3 (6.5-9.7)
26.3 (5.6-47.8)
244 (115-357)
13.7 (10.3-18.7)
88 (72-110)
6.7 (4.7-9.8)
134 (131-136)
35 (23-51)
7.1 (6.0-8.5)
71.3 (18.0-263.2)
2.66 (0.65-10.86)
0.72 (0.56-0.92)
1.02 (0.14-7.26)
0.34 (0.07-1.68)
0.83 (0.73-0.94)
1.25 (0.75-6.76)
3.47 (0.46-26.18)
0.73 (0.53-1.02)
Arterial blood gas:
pCO
2
 in kPa (IQR)*
pO
2
 in kPa (IQR)*
3.7 (3.3-4.1)
8.0 (5.0-9.5)
4.4 (4.0-4.8)
8.7 (7.6-11.0)
0.00 (0.00-0.21)
0.07 (0.00-1.16)
PSI class (%): 
PSI class I-III 
PSI class IV-V
5 (71.4)
2 (28.6)
83 (59.3)
57 (40.7) 0.58 (0.11-3.11)
Data are presented as number (%) or median (IQR). ASAT = aspartate aminotransferase; BP = blood pressure; BUN = blood urea nitrogen; CI = 
confidence interval; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; ICU = intensive care unit; IQR = interquartile range; 
NA = not applicable; PSI = pneumonia severity index; WBC count = white blood cell count; ∞missing data of 9 patients; *variables were log normally 
transformed for regression analysis.
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the Bonferroni correction for multiple testing with 26 
variables. To identify variables predicting psittacosis, 
logistic regression analysis was conducted in a univariate 
model. Variables which were not normally distributed 
were log-normally transformed to improve distribution. 
A multivariate analysis was not possible due to the small 
number of psittacosis patients. Data were analysed with 
SPSS statistical software for Windows, version 22.0. 
R E SU LT S
Psittacosis diagnosis
In total, 304 CAP patients were enrolled in the original 
trial. Sputum was available in 154/304 patients for analysis 
with C. psittaci PCR. In seven patients the PCR reaction of 
sputum was inhibited. Therefore, 147/304 (48.4%) patients 
were eligible for further analysis, of which 77 patients 
received dexamethasone and 70 patients placebo in the 
original study. Of the 147 patients, six (4.1%) patients were 
diagnosed with psittacosis based on a positive PCR result. 
In 119/147 (81.0%) patients serological analysis for the 
presence of Chlamydia antibodies by CFT was performed 
as well. In nine patients, serum was positive on CFT. 
A confirmation with micro-immunofluorescence was 
positive in five out of nine patients, and four of these five 
were also positive on PCR. One PCR-positive patient was 
seronegative and one was sero-inconclusive. Based on our 
diagnostic criteria, we considered the one patient who was 
PCR negative but CFT and micro-immunofluorescence 
positive to be positive for psittacosis. In total, 7/147 (4.8%) 
patients were diagnosed with psittacosis based on PCR 
and serology results. Table 2 shows an overview of the 
test results. No other pathogens were detected in these 
seven patients. None of these patients were known to be 
involved in an outbreak. In three of six patients, sputum 
was available in storage for genotyping; two patients had 
genotype A, one patient genotype B.
In our cohort, most CAPs were caused by S. pneumoniae 
(38/147, 25.9%), followed by C. burnetii (12/147, 8.2%).10 
The latter was high due to a national outbreak of Q fever.13 
Haemophilus influenzae was detected in six patients and 
Legionella species in five patients. In the 47 patients in 
whom Chlamydia pneumoniae PCR was performed, no 
positive results were found.
Of the 157/304 patients in whom no sputum was 
available for PCR, paired CFT was performed in 93 
(59.2%) patients. Of these patients, three were positive on 
CFT, but specificity for C. psittaci was not confirmed by 
micro-immunofluorescence.
Description of psittacosis patients
Median age of the seven patients with a C. psittaci CAP was 
54 years (IQR 46-58) and 71.4% were male. The median 
interval between onset of disease and admission to hospital 
in patients with psittacosis was 5.0 days (IQR 3.0-5.0 days). 
Table 2. Test results for detection of Chlamydia psittaci by polymerase chain reaction, complement fixation test, 
and micro-immunofluorescence test
PCR Complement fixation test Micro-immunofluorescence test Psittacosis
Patient First sample Second 
sample
Result First sample Second 
sample
Result
1 + <1:4 >1:128 + <1:16 1:64 + +
2 + <1:4 >1:128 + 1:32 1:128 + +
3 + <1:4 1:256 + <1:16 1:64 + +
4 + <1:10 1:80 + <1:16 1:256 + +
5 + >1:160 >1:160 NC 1:128 Missing NC +
6 + <1:4 <1:4 - <1:16 1:16 - +
7 - <1:4 1:80 + <1:16 1:64 + +
8 - <1:4 1:16 + <1:16 <1:16 - -
9 - <1:4 1:128 + <1:16 Missing NC NC
10 - <1:10 1:80 + <1:16 Missing NC NC
11 - <1:4 1:64 + <1:16 Missing NC NC
NC = non conclusive; PCR = polymerase chain reaction. Interval between first (day of admission) and second serum sample was at least 10 days; a 
fourfold or greater rise of the antibody titre in the convalescent versus the acute-phase serum was considered indicative for a recent C. psittaci infection 
(sequence 1: <4, 4, 8, 16, etc., or 1: <10, 10, 20, 40, etc. for CFT and 1: <16, 16, 32, 64, etc. for MIF).
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Of the seven patients, five patients initially reported a 
positive history of bird contact, one a negative history, and 
for one patient history was not documented in the medical 
record. For this patient information on bird contact could 
be found in the Dutch notification database: a dead bird 
in the garden was reported. Table 3 shows an overview of 
clinical parameters of the seven psittacosis patients.
Characteristics of C. psittaci versus other pathogens
Baseline characteristics of the seven psittacosis patients 
were compared with the 140 CAP patients with other or 
unknown aetiology (table 1). There were no significant 
clinical or demographical differences between these two 
aetiological groups. Psittacosis patients had a higher 
median temperature (39.6 °C, IQR 38.8-40.0 vs. 38.2 °C, 
IQR 37.4-38.9) but lower white blood cell count (7.4 x109/l, 
IQR 6.9-10.4 vs. 13.7 x109/l, IQR 10.3-18.7) on admission, 
with ORs of 4.25 (95% CI 1.46-12.35) and 0.72 (95% 
CI 0.56-0.92), respectively. All odds ratios with 95% 
confidence intervals can be found in table 1. 
Therapy
In five patients antibiotics adequate for psittacosis 
treatment were started in the emergency department 
(tetracycline, macrolide or quinolone antibiotics). In 
one patient adequate treatment was started later during 
admission based on a positive C. psittaci PCR. One patient 
was treated with β-lactam only. Length of stay did not 
Table 3. Clinical and demographical characteristics of seven hospitalised patients with community-acquired 
pneumonia caused by Chlamydia psittaci 
Pt Age Gender Bird contact Symptoms on 
admission
Days of 
symptoms
Pulmonary 
medical 
history
Treatment LOS in 
days
PCR
1 46 Male Unknown
CIDC 
database: 
deceased bird 
in garden
Dyspnoea, 
Productive 
coughing, 
Abdominal and 
thoracic pain
2 No β-lactam, later 
cephalosporin 
and macrolide
13.5 Positive
Strain B
2 26 Female Parrot at 
home
Dyspnoea, 
coughing, 
vomiting, 
thoracic and 
low lumbar 
pain, fainting, 
dizziness 
5 No β-lactam 3.5 Positive
Strain A
3 55 Male Two birds at 
home
Coughing, 
diarrhoea, 
headache
7 No β-lactam and 
macrolide
6.5 Positive
4 50 Male Bird contact 
mentioned
Fever, productive 
coughing, 
headache, 
nausea, 
vomiting, 
abdominal pain
5 No Tetracycline 17.0 Positive
Strain A
5 54 Male Pigeons Fever, coughing, 
dyspnoea, 
confusion
5 Aspergillus 
pneumonia, 
yearly 
pneumonia
Cephalosporin 
and quinolone, 
later 
erythromycin 
(on ICU) 
12.5 (ICU 
day after 
admission)
Positive
6 65 Male >100 different 
birds at home
Headache, 
muscle ache, 
loss of appetite
3 History of 
psittacosis
β-lactam and 
quinolone
4.5 Positive
7 58 Female No Fever, muscle 
ache, loss 
of appetite, 
headache
4 No cephalosporin 
and tetracycline, 
afterwards 
doxycycline and 
amoxicillin-
clavulanic acid
8.5 Negative
CIDC = Centre for Infectious Disease Control; LOS = length of hospital stay; PCR = polymerase chain reaction.
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differ between these two patients and the five patients who 
immediately received antibiotics regarded as adequate for 
the treatment for psittacosis. No patients died during the 
hospital stay.
D I S CUS S I ON 
In this study, PCR to detect C. psittaci was performed 
in all CAP patients for whom sputum was available. We 
found a much higher incidence of psittacosis (4.8%) than 
previously reported. 
In most studies on CAP, psittacosis diagnostics are 
performed with serological tests only and no PCR.14 A 
recent study on aetiology in patients hospitalised with 
CAP in the United States did not perform C. psittaci 
diagnostics at all.15 A recent study from Germany did 
perform Chlamydia species PCR on pharyngeal swab 
specimens in all CAP patients presenting to the emergency 
department, and found an incidence of 2.1% for C. 
psittaci.9 PCR leads to a quick diagnosis and lacks broad 
genus cross-reactivity.16 Furthermore, C. psittaci sputum 
strains can be genotyped, which is relevant for public 
health notification and source detection and control. 
However, sputum or bronchial alveolar lavage to perform 
a PCR are not always available. In these cases, serology 
can be informative. Moreover, in our study, one patient 
with a negative PCR had a positive CFT confirmed 
by micro-immunofluorescence. Including only patients 
in whom both PCR and serology were performed, the 
incidence of C. psittaci would be even higher in this study: 
7/119 (5.8%). In this small population, we cannot explain 
why some patients were PCR positive and serology negative 
and vice versa. Serology does have the disadvantage of 
cross-reactivity with other Chlamydia strains. Furthermore, 
to confirm psittacosis two serum samples have to be 
drawn with an interval of at least ten days to detect a 
fourfold increase in antibody titre. Therefore, serology 
can only be used to diagnose psittacosis in retrospect and 
is mainly of additional value to optimise epidemiological 
investigations. Figure 1 shows reported psittacosis in 
the Netherlands in the period of study inclusion, based 
on the National Notification Database of the Centre for 
Infectious Disease Control. Nationally, this figure shows 
more psittacosis diagnosed serologically than by PCR. 
Regionally, in the areas where the study was conducted (in 
the centre of the Netherlands) and consequently psittacosis 
PCR was performed more routinely, the number of cases 
of PCR-confirmed psittacosis was higher compared with 
other areas. However, information on the number of PCRs 
and serology tests performed per region is unknown. The 
high number of reported psittacosis in the south-east area 
was mainly due to an outbreak of psittacosis after a bird 
fair in November 2007.17
We addressed the question whether we could identify 
clinical parameters that discriminate psittacosis from 
CAPs caused by other pathogens. Due to the small sample 
size, the power of the statistical analysis was limited. The 
white blood cell count was almost normal in psittacosis 
patients, a finding consistent with a study on 135 serology-
confirmed psittacosis cases.18 Since elevated white blood 
cell count was one of the inclusion criteria of the original 
clinical trial, this could mean that psittacosis patients 
were less likely to be included and the real psittacosis 
incidence is even higher. In accordance with a study on 
the differences between C. psittaci and L. pneumophila 
in patients admitted to the ICU, patients with psittacosis 
seemed to have less comorbidities compared with those 
with CAP with other aetiologies, although this difference 
was not significant in our study.19 Further research with 
larger groups of psittacosis patients is needed to establish 
whether psittacosis can be identified as a separate clinical 
entity. This lack of specific alerting symptoms implies that 
doctors should be aware of the possibility of psittacosis 
in any case of CAP. In our study, one patient was treated 
with a β-lactam antibiotic only. This antibiotic is not 
recommended for the treatment of psittacosis, because C. 
psittaci lacks peptidoglycan. Either β-lactam antibiotics 
Figure 1. Reported psittacosis in the Netherlands in 
the period November 2007 until September 2010
Incidence per inhabitants is calculated using the population per 
municipal health service regions on 1 January 2010 (Source: Statistics 
Netherlands). Source of reported psittacosis: National notification 
database (Osiris). The hospital on the left is St. Antonius Hospital in 
Nieuwegein, on the right is Gelderse Vallei Hospital in Ede.
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are also somewhat effective in psittacosis or the patient 
recovered due to the natural course of the disease. 
Some limitations of the study must be mentioned. First, 
as mentioned previously, the number of psittacosis 
cases is small which limits statistical analysis. Second, 
since only two hospitals participated in this study it is 
unknown whether the results can be generalised. Third, 
CFT detects antibodies to Chlamydia species, but is not 
specific for C. psittaci due to cross-reactivity between the 
different Chlamydia species. Therefore, we performed 
micro-immunofluorescence to confirm the specificity 
of CFT results. It is assumed that micro-immuno-
fluorescence does have species specificity. Finally, we 
included only patients in whom sputum was available 
for PCR diagnostics, which was 48.4% of the total CAP 
cohort. In the non-sputum group in whom serological 
analysis was performed, we found no evidence of an 
excess of psittacosis. On the contrary, there were less CFT/ 
micro-immunofluorescence serologically positive patients 
in the non-sputum group than expected: 0/94 in the 
non-sputum group compared with 5/119 in the sputum 
group (p=0.07). In the literature, there is no evidence that 
patients with psittacosis produce more sputum compared 
with CAPs with other aetiology. 
In conclusion, in these two Dutch hospitals, where 
psittacosis PCR was performed if sputum samples were 
available, C. psittaci was more common as CAP-causing 
pathogen than previously reported. C. psittaci PCR is a 
fast method and sputum availability allows genotyping. 
Serology can be added to optimise epidemiological 
investigations.
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